ALM - 6097

YHD - YHD Delayed Price. Currency in USD
As of 6:07PM EDT. Market open.
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Business Wire9 days ago

    Sinequa Raises $23M to Accelerate the Transition Beyond Data-Driven to an Information-Driven Economy

    Sinequa, a recognized leader in the AI-powered search and analytics market, today announced a $23 million Series B funding round led by Jolt Capital and supported by Troismer BVBA, an existing investor. With this new funding, Sinequa will invest in its award-winning AI-powered search and analytics platform that connects knowledge workers in some of the world’s largest organizations with the information, expertise and insights necessary to make information-driven decisions. According to IDC, by 2020 organizations able to analyze enterprise content and data assets to deliver actionable information and insights will achieve an extra $430 billion in productivity benefits over their less analytically oriented peers.

  • Business Wire4 months ago

    HitGen and Almirall Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration

    HitGen Ltd announced that the company has entered into a research collaboration with Almirall to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for Almirall. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments from Almirall.

  • Thermi Receives Notice Of Complete And Satisfactory Closure Of FDA's "Vaginal Rejuvenation" Inquiry
    PR Newswire8 months ago

    Thermi Receives Notice Of Complete And Satisfactory Closure Of FDA's "Vaginal Rejuvenation" Inquiry

    IRVING, Texas, Nov. 15, 2018 /PRNewswire/ -- Thermi®, an Almirall, S.A. company, today announced that it has received a notice of completion to a U.S. Food and Drug Administration (FDA) inquiry on products used in "vaginal rejuvenation" procedures. Thermi received an "It has come to our attention" notice from the FDA on July 24, 2018 regarding specific claims about the company's ThermiVa® device in the United States. ThermiVa, a non-ablative radiofrequency application, has been cleared by the FDA for use in dermatological and general surgical procedures for electrocoagulation and hemostasis.